Buprenorphin/Naloxon "G.L. Pharma" 4+1 mg resoribletter, sublinguale Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

buprenorphin/naloxon "g.l. pharma" 4+1 mg resoribletter, sublinguale

g.l. pharma gmbh - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 4+1 mg

Ranivisio Den Europæiske Union - dansk - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiske - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Pregabalin Mylan Pharma Den Europæiske Union - dansk - EMA (European Medicines Agency)

pregabalin mylan pharma

mylan s.a.s. - pregabalin - anxiety disorders; neuralgia; epilepsy - antiepileptika, - epilepsypregabalin mylan pharma er indiceret som adjuverende behandling til voksne med partielle anfald med eller uden sekundær generalisering. generaliseret angst disorderpregabalin mylan pharma er indiceret til behandling af generaliseret angst (gad) hos voksne.